Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Drug Therapy for Rheumatoid Arthritis in Adults

Slide: 18 of 45

Summary of Benefits: Comparative Effectiveness of Oral DMARDs for Rheumatoid Arthritis

The comparative benefits of oral disease-modifying anti-rheumatic drugs (DMARDs) may be summarized as follows:

  • Leflunomide and methotrexate (MTX; 7.5 to 25 mg/week) have similar effects on symptom response, radiographic change, and functional capacity. The strength of evidence for this finding is low.
  • Leflunomide may be superior to sulfasalazine for improving functional capacity. The strength of evidence for this finding is low.
  • Sulfasalazine and MTX (7.5 to 25 mg/week) have similar effects on symptoms, disease activity, functional capacity, and limiting radiographic changes (in patients with rheumatoid arthritis for <3 years). The strength of evidence for this finding is moderate.